UAS Labs Finalizes an Impactful Partnership with Lottus and Dr. Pinaki Panigrahi
UAS Laboratories, LLC (Madison, WI, USA) has continuously shown support for the probiotic industry as well as the innovators within it. With that, they are pleased to announce their most recent licensing agreement with Lottus, LLC and Dr. Pinaki Panigrahi, MD, PhD, FIDSA, a world-renowned pediatric infectious disease expert.
The licensing agreement provides UAS Labs exclusive manufacturing rights in addition to the promotion and sale of Lactobacillus plantarum PPLP-217™, a strain extensively studied by Dr. Panigrahi. This signed agreement showcases a mutual respect and desire to partner now, and in the future.
While UAS Labs has an existing portfolio of probiotic strains Kevin Mehring, President & CEO, has voiced his excitement for the science and the social impact of this strain. Mehring states, “The research of Dr. Panigrahi has made a lasting impression on me as a business owner and as a father. This strain has been the focus of ground-breaking studies in neonates and young infants with astonishing results. I am thrilled to join forces with Dr. Pinaki Panigrahi who we will continue to recognize with the “PP” at the beginning of the L. plantarum strain designation.” He continues, “This individual strain is the epitome of our vision here at UAS and together we continue to enhance wellness and quality of life through innovative probiotic solutions”.
The PPLP-217™ strain of L. plantarum has gone through development stages including screening, testing and multiple phases of clinical research. The most recent research was a randomized, double-blind, placebo-controlled clinical trial of 4,556 infants within the first two months of life. The treatment was so successful that an oversight panel stopped the trial early as it would have been unethical to continue depriving half the newborns of the probiotic. This trial was published in the prestigious journal Nature and has been cited over 125 times. Discover magazine selected the work as one of 100 most interesting scientific stories of the year. The clinical trial and its ramifications were covered by The New York Times, The Atlantic, NPR and other major newspapers around the world.
Dr. Panigrahi Monitoring an Infant During Clinical Trial
Dr. Panigrahi said, “I am pleased to have formed this partnership with Kevin and the team at UAS. I have dedicated my life’s work to this strain and consider our agreement to be mutually beneficial. While the research to-date has been second-to-none, it is only the beginning!”.
In addition to the strain partnership Kevin Mehring and Dr. Panigrahi, along with additional investors, are launching a foundation focused on bringing L. plantarum PPLP-217™ to those in need. Investing in this strain offers the opportunity to not only invest in their product portfolio but also support a greater cause through the Healthy Bellies, Healthy Babies foundation. A percent of all profits will be used to bring this solution to resource-constrained settings.
UAS Laboratories LLC has delivered the highest quality, science-backed probiotics to the marketplace since 1979. Strictly dedicated to probiotic manufacturing, UAS is committed to designing innovative and effective formulations that strive to enhance wellness and quality of life.
Lakeview Equity Partners is a private equity investment fund that focuses on investments in Midwest-based, middle market companies. Lakeview Equity’s mission is to identify and invest in strong, well-managed companies to help them achieve continued growth and profitability and support ownership change, including ownership opportunities for managers and employees.
